Study Evaluating the Quality and Effects of Lion's Mane Product on Cognitive Health

Inclusion Criteria:

• Individuals 40-75 years old, inclusive

• Has self-reported concerns with reduced memory, focus and cognitive decline

• Cognitive Failures Questionnaire score of mild to moderate at screening

• Interested in understanding more about their cognitive health and have chosen havechosen to use the study product

• Willing to do a 4-week washout from any supplements for memory or cognitive functionprior to randomization

• Willing to do a 4-week washout prior to randomization from supplements with mushroomcompounds or consuming mushrooms known to impact NGF. This includes but may not belimited to: Reishi (ganoderma lucidum), cordyceps (cordyceps militaris or cordycepssinensis), Lion's mane or Coral Tooth Fungus (hericium coralloides), turkey tail (trametes versicolor), Chage (inonotus obliquus), Maitake (grifola frondosa).

• If taking prescription medications for sleep (e.g. Benzodiazepines, zolpidem,zaleplon), or other class of medication for sleep, must be on a "stable dose" for atleast 4 weeks prior to enrollment. "Stable dose" is defined as no changes in dosageor frequency of the specified medications for at least 4 weeks prior to enrollmentand throughout the study period.

• If regularly consuming alcohol, must be willing to stay on a stable amountthroughout the study period and to log alcohol consumption.

• In good general health at the time of screening (Investigator discretion).

• Able to read and understand English.

• Able to read, understand, and provide informed consent.

• Able to use a personal smartphone device and laptop, download Chloe by PeopleScience and use the BrainHQ web-based assessment platform.

• Able to receive shipment of the product at an address within the United States.

• Able to complete study assessments over the course of up to 9 weeks.

Exclusion Criteria:

Any potential participants who:

• Do not have a smartphone and/or internet access.

• Concomitant Therapies:

• Participants taking prescription medication for sleep (e.g. Benzodiazepines,zolpidem, zaleplon) not on a stable dose for at least 4 weeks

• Participants receiving Cognitive Behavioral Therapy for Insomnia (CBTi)

• Participants receiving any investigational therapies or treatments within 30days prior to randomization.

• Other Illnesses or Conditions: Participants who have the following conditions orcomorbidities are excluded:

• Diagnosis of Alzheimer's disease or dementia

• Diagnosed neurological condition or assessed as having a learning/behaviouralor neurodevelopmental difference such as dyslexia or ADHD

• Have a visual impairment that cannot be corrected with glasses or contactlenses, including red green color blindness

• Deafness or untreated age-related hearing loss

• Confirmed diagnoses of the following sleep disorders: Narcolepsy, Restless LegSyndrome, Circadian Rhythm Disorders

• Current or prior history of psychotic disorder

• Diagnosed with Alcohol or Substance Abuse Disorder

• Currently pregnant, planning to become pregnant at any time during the study,or breastfeeding

• Have a significant illness, disease or condition which, in the opinion of theprincipal investigator, may impact their ability to participate in the trial orimpact the trial outcomes

• Long Covid including persistent feelings of brain fog

• Participants using any nicotine and cannabis-containing products

• Known hypersensitivity or previous allergic reaction to Lion's mane orfunctional mushrooms.

• Are unlikely for any reason to be able to comply with the trial or consideredunsuited for participation in the study by the Principal Investigator.